Nuo Therapeutics, Inc.
AURX
Rank in Stocks
#22573
Nuo Therapeutics, Inc. operates as a regenerative medicine company,... Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.
Share Price
$1.07
Last synced: 2026-11-10
Market Cap
$51.80M
Change (1 day)
0.00%
Change (1 year)
-49.29%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Nuo Therapeutics, Inc. (AURX)
Category
Healthcare
Operating Margin for Nuo Therapeutics, Inc. (AURX)
Operating Margin as of November 2026 TTM: -33.32%
According to Nuo Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -33.32%. At the end of 2025 the company had an operating margin of -75.95%.
Operating Margin history for Nuo Therapeutics, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -33.32% | -56.13% |
| 2025 | -75.95% | -57.81% |
| 2024 | -180.04% | -65.42% |
| 2023 | -520.65% | -82.40% |
| 2022 | -2,958.21% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | -100.00% |
| 2019 | -663.03% | 503.96% |
| 2018 | -109.78% | -94.90% |
| 2017 | -2,154.40% | 467.34% |
| 2016 | -379.74% | 5.79% |
| 2015 | -358.96% | 19.12% |
| 2014 | -301.35% | 92.70% |
| 2013 | -156.38% | 28.12% |
| 2012 | -122.06% | 151.72% |
| 2011 | -48.49% | -64.90% |
| 2010 | -138.15% | -17.25% |
| 2009 | -166.95% | -55.78% |
| 2008 | -377.57% | 37.07% |
| 2007 | -275.46% | 29.02% |
| 2006 | -213.50% | -56.58% |
| 2005 | -491.68% | -31.21% |
| 2004 | -714.77% | 88.03% |
| 2003 | -380.13% | -24.58% |
| 2002 | -504.05% | -96.03% |
| 2001 | -12,702.65% | 21.01% |
| 2000 | -10,497.45% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -101.16% |
US
|
|
| -149.01% | -95.53% |
US
|
|
| 25.57% | -100.77% |
AU
|
|
| 31.23% | -100.94% |
BE
|
|
| 29.35% | -100.88% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Nuo Therapeutics, Inc.'s operating margin
What is Nuo Therapeutics, Inc.'s operating margin?
Nuo Therapeutics, Inc.'s operating margin is -33.32%, as of Nov 2026.
What was Nuo Therapeutics, Inc.'s operating margin in 2025?
In 2025, Nuo Therapeutics, Inc.'s operating margin was -75.95%, compared with -180.04% in 2024.
How has Nuo Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Nuo Therapeutics, Inc.'s operating margin was highest in 2021 (0.00%) and lowest in 2022 (-2,958.21%).
How does Nuo Therapeutics, Inc.'s operating margin compare with similar companies?
Nuo Therapeutics, Inc.'s operating margin (-33.32%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.